Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ARMOUR’s MONONINE MONOCLONAL FACTOR IX APPROVED BY FDA

Executive Summary

ARMOUR's MONONINE MONOCLONAL FACTOR IX APPROVED BY FDA on Aug. 20 for the "prevention and control of bleeding in Factor IX deficiency" in patients with Hemophilia B. Monoclonally-purified Mononine Coagulation Factor IX carries an average wholesale price of $1.04 per unit. The clotting factor is the "world's first monoclonal antibody (MAb) purified Hemophilia B therapy," the Rhone-Poulenc Rorer subsidiary states. Mononine is supplied in single dose vials of 250, 500 and 1000 IUs. "When reconstituted as directed to approximately 100 units/ml, Mononine should be administered at a rate of approximately 2.0 ml per minute," approved labeling notes. Each ml of the reconstituted concentrate contains approximately 100 IU of Factor IX and non-detectable levels of Factor II, VII and X. Mononine is contraindicated in patients hypersensitive "to mouse protein." Two other Factor IX biologics also were recently approved by FDA: Alpha Therapeutics' AlphaNine SD (Coagulation Factor IX) on Aug. 26 and Oestereichisches' Bebulin VH Immuno (Factor IX Complex) on Aug. 19. AlphaNine SD is an improved version of Alpha Therapeutics' AlphaNine, which was approved on Dec. 31, 1990 ("The Pink Sheet" Jan. 7, 1991, p. 7). The firm filed a PLA amendment in June 1991 to include the use of solvent/detergent as a viral inactivation process in its Factor IX product. The product's launch date is planned for Oct. 1. A third generation product evolved from Alpha's first generation Profilnine, AlphaNine SD has an improved viral inactivation step utilizing the solvent/detergent, tri-n-butyl phosphate (TNBP) and Polysorbate 80. The purification process also reduces the non-Factor IX proteins to "very low levels," augmenting the safety and purity of the product, the company said. Vienna, Austria-based Oesterreichisches Institut's Factor IX Complex, vapor heated biologic, Bebulin VH Immuno, is a purified, sterile, stable, freeze-dried concentrate of the coagulation Factor IX, Factor II (Prothrombin) and Factor X (Stuart Prower) as well as low amounts of Factor VII. The product also contains small amounts of heparin. "No clinical studies have been conducted to show benefit from this product for treating deficiencies other than Factor IX deficiency," approved labeling notes.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS021419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel